سعر لاكسولاك 3.35 جم/5 مل شراب 300 مل 2024

Laxolac lactulose 3.35 g/5 ml oral syrup, 300 ml bottle (MUP, Egypt); osmotic laxative also used in hepatic encephalopathy.

• Treatment of constipation.Population: Adults and childrenelectronic medicines compendium (emc)
• Treatment of hepatic encephalopathy (hepatic coma).Population: Adultselectronic medicines compendium (emc)

• Very common: diarrhoea. Common: flatulence, abdominal pain, nausea, vomiting. Uncommon: electrolyte imbalance due to diarrhoea. Not known: hypersensitivity reactions, rash, pruritus, urticaria (post-marketing). Flatulence in the first days usually resolves.International label, equivalent formulation · electronic medicines compendium (emc)

• Hypersensitivity to lactulose or any excipient; galactosaemia; gastrointestinal obstruction, perforation or risk of perforation.International label, equivalent formulation · electronic medicines compendium (emc)

• Evaluate painful abdominal symptoms of undetermined cause before treatment to exclude perforation or obstruction. Chronic use of unadjusted doses and misuse can cause diarrhoea and electrolyte disturbance. Higher doses used in hepatic encephalopathy may need consideration in diabetics. The UK product contains lactose, galactose and fructose residues: not for hereditary galactose or fructose intolerance, total lactase deficiency or glucose-galactose malabsorption; caution in lactose intolerance. Laxative use in children should be exceptional and supervised.International label, equivalent formulation · electronic medicines compendium (emc)
• Theoretical hazard during electrocautery at proctoscopy or colonoscopy because of hydrogen gas accumulation; patients on lactulose should have thorough bowel cleansing with a non-fermentable solution. Infants receiving lactulose may develop hyponatraemia and dehydration.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Oral anti-infectives (e.g. neomycin)Elimination of colonic bacteria may interfere with lactulose degradation and colonic acidification; monitor the patient closely during concomitant oral anti-infective therapy.DailyMed (U.S. National Library of Medicine)

• No effects during pregnancy are anticipated since systemic exposure to lactulose is negligible; can be used during pregnancy.International label, equivalent formulation · electronic medicines compendium (emc)
• US label: animal reproduction studies showed no harm to the fetus, but there are no adequate and well-controlled studies in pregnant women; use in pregnancy only if clearly needed.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• No effects on the breastfed infant are anticipated since maternal systemic exposure is negligible; can be used during breastfeeding.International label, equivalent formulation · electronic medicines compendium (emc)

• Lactulose: Broken down by colonic bacteria into low-molecular-weight organic acids that lower colonic pH and, by osmosis, increase the volume of colonic contents and stimulate peristalsis; in hepatic encephalopathy it traps ammonia in ionised form and alters bacterial nitrogen metabolism.